Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
General Internal Medicine
•
Breast Cancer, Non-metastatic
Is there any definitive contraindication to use tamoxifen in patients with a brain aneurysm that is being monitored?
Related Questions
Given the HELEN-006 trial results, under what circumstances, if any, would you consider de-escalated neoadjuvant therapy in HER2-positive breast cancer?
In a patient with BRCA2 mutation and contralateral axillary recurrence of ER+ IDC with an ESR1 CCDC170 fusion on NGS testing, would you use standard adjuvant AI therapy or consider adjuvant SERD therapy (fulvestrant/elacestrant)?
Would you discontinue or dose-reduce tamoxifen in a patient who developed hepatic steatosis?
With the recent FDA approval of adjuvant ribociclib, how are you deciding between ribociclib and abemaciclib for high risk HR+/HER2− early breast cancer?
How do the results of INSEMA and SOUND impact the decision of omitting SLND in young women with breast cancer and offering adjuvant RT to patients who would otherwise be candidates for omission?
What is your preferred method of surveillance after mastectomy?
Would you offer neoadjuvant pembrolizumab to a TNBC patient with multiple pulmonary nodules and bilateral hilar adenopathy secondary to asymptomatic sarcoidosis (biopsy proven)?
How would you manage a young premenopausal woman with hormone receptor-positive micrometastatic breast cancer in two axillary lymph nodes, but with only DCIS on breast surgical pathology?
How do you approach the RxPonder data in premenopausal women with ER/PR+, HER2 negative, pN1, many of whom now qualify for CDK 4/6 inhibitors in adjuvant setting besides endocrine therapy (+/- OFS) if the RS 0-13 and 14-25?
Would you offer adjuvant chemotherapy for triple negative invasive papillary carcinoma of breast?
